BriaCell Therapeutics Corp. (BCTX)
After hours:
- Baystreet
Stocks in play: BriaCell Therapeutics Corp
Announced a research collaboration agreement with Harvard Medical School in support of a project led ...
- GlobeNewswire
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
PHILADELPHIA and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, today announced a research collaboration agreement with Harvard Medical School in support of a project led by Joan S. Brugge, PhD, a faculty member. The project aims to discover new targets that may lead to the development of novel anti
- GlobeNewswire
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action, rapidly destroyed tumors in patients who matched Bria-IMT™ HLA types, supporting BriaCell’s platform strategy of developing off-the-shelf personalized immunotherapy for multiple cancer indications.The clinical data, previously reported, included rapid tumor reduction and extended survival. PHILADELPH
